648 related articles for article (PubMed ID: 27432042)
1. A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism.
Comerota AJ; Ramacciotti E
Am J Med Sci; 2016 Jul; 352(1):92-106. PubMed ID: 27432042
[TBL] [Abstract][Full Text] [Related]
2. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review.
Gómez-Outes A; Lecumberri R; Suárez-Gea ML; Terleira-Fernández AI; Monreal M; Vargas-Castrillón E
J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):490-500. PubMed ID: 25802423
[TBL] [Abstract][Full Text] [Related]
3. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
[TBL] [Abstract][Full Text] [Related]
4. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
Finks SW; Trujillo TC; Dobesh PP
Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821
[TBL] [Abstract][Full Text] [Related]
5. Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.
Imberti D; Pomero F; Benedetti R; Fenoglio L
Intern Emerg Med; 2016 Oct; 11(7):895-900. PubMed ID: 27550399
[TBL] [Abstract][Full Text] [Related]
6. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
Leung TS; Law EH
Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
[TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.
Imberti D; Pomero F; Mastroiacovo D
Blood Transfus; 2020 Jan; 18(1):49-57. PubMed ID: 31184579
[TBL] [Abstract][Full Text] [Related]
8. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
9. New oral anticoagulants for the treatment of venous thromboembolism.
Agnelli G; Becattini C; Franco L
Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
[TBL] [Abstract][Full Text] [Related]
10. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
[TBL] [Abstract][Full Text] [Related]
11. Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism.
Bertoletti L; Ollier E; Duvillard C; Delavenne X; Beyens MN; De Magalhaes E; Bellet F; Basset T; Mismetti P; Laporte S
Pharmacol Res; 2017 Apr; 118():33-42. PubMed ID: 27350265
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis.
Sindet-Pedersen C; Pallisgaard JL; Olesen JB; Gislason GH; Arevalo LC
Thromb Res; 2015 Oct; 136(4):732-8. PubMed ID: 26277682
[TBL] [Abstract][Full Text] [Related]
13. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
[TBL] [Abstract][Full Text] [Related]
14. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
Ay C; Beyer-Westendorf J; Pabinger I
Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
[TBL] [Abstract][Full Text] [Related]
15. Long-term benefits of preventing venous thromboembolic events.
Cohen AT
Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
[TBL] [Abstract][Full Text] [Related]
16. Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta-analysis, and decision analysis.
Djulbegovic M; Lee AI; Chen K
J Eval Clin Pract; 2020 Feb; 26(1):7-17. PubMed ID: 31190408
[TBL] [Abstract][Full Text] [Related]
17. The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry.
Bauersachs R; Agnelli G; Gitt AK; Monreal M; Mismetti P; Willich SN; Laeis P; Fronk EM; Bramlage P; Cohen AT;
Thromb Res; 2017 Sep; 157():181-188. PubMed ID: 28780343
[TBL] [Abstract][Full Text] [Related]
18. [Oral anticoagulants for primary and secondary prevention of venous thromboembolism].
Gavorník P; Dukát A; Gašpar Ľ; Gubo G; Hučková N
Vnitr Lek; 2016; 62(9):746-750. PubMed ID: 27715076
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
Weitz JI; Jaffer IH
Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
[TBL] [Abstract][Full Text] [Related]
20. Is it reasonable to use a lower DOAC dose in some patients with VTE? NO.
Dentali F; Fantoni C
Intern Emerg Med; 2017 Aug; 12(5):565-567. PubMed ID: 28656545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]